#1 Clinical Trials Search in Europe

Palbociclib

Palbociclib, also known as PD-0332991, is an oral medication being studied in clinical trials for various types of cancer. It works by inhibiting specific proteins called cyclin-dependent kinases (CDK) 4 and 6, which are involved in cell division. By blocking these proteins, palbociclib may help stop or slow the growth of cancer cells. This article summarizes key information about ongoing clinical trials investigating palbociclib’s effectiveness and safety in treating different cancers.

Table of Contents

What is Palbociclib?

Palbociclib, also known by its brand name Ibrance, is a medication used in the treatment of certain types of cancer[2]. It belongs to a class of drugs called CDK4/6 inhibitors, which work by targeting specific proteins in cancer cells to slow down or stop their growth[1]. Palbociclib is primarily used in the treatment of advanced breast cancer, but researchers are also studying its potential in other types of cancer.

How Palbociclib Works

Palbociclib works by inhibiting two important proteins in cancer cells called CDK4 and CDK6 (cyclin-dependent kinases 4 and 6)[1]. These proteins play a crucial role in cell division and growth. By blocking their activity, palbociclib can help slow down or stop the growth of cancer cells. This mechanism of action makes palbociclib particularly effective in treating certain types of cancer that rely heavily on these proteins for their growth.

Conditions Treated with Palbociclib

Palbociclib is primarily used to treat the following conditions:

  • Advanced Breast Cancer: Specifically, palbociclib is used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in postmenopausal women[3]. This type of breast cancer is driven by hormones and does not have high levels of the HER2 protein.
  • Head and Neck Cancer: Researchers are investigating the use of palbociclib in combination with other drugs for the treatment of squamous cell carcinoma of the head and neck (SCCHN)[4].
  • Other Solid Tumors: Clinical trials are exploring the potential of palbociclib in treating other types of solid tumors, including pancreatic cancer[5].

How Palbociclib is Administered

Palbociclib is typically administered as follows:

  • Oral Capsules: Palbociclib is taken by mouth in the form of capsules[6].
  • Dosing Schedule: The usual dosing schedule is 125 mg once daily for 21 consecutive days, followed by 7 days off treatment. This 28-day cycle is then repeated[6].
  • With Food: Palbociclib should be taken with food to ensure proper absorption[4].
  • Continuous Treatment: Patients typically continue taking palbociclib as long as they are benefiting from the treatment and not experiencing severe side effects[7].

Combination Therapies

Palbociclib is often used in combination with other cancer treatments to enhance its effectiveness. Common combination therapies include:

  • Palbociclib + Letrozole: This combination is used for postmenopausal women with HR+, HER2- advanced breast cancer[3]. Letrozole is a type of hormone therapy that helps block the production of estrogen, which can fuel the growth of certain breast cancers.
  • Palbociclib + Fulvestrant: Another combination used in the treatment of HR+, HER2- advanced breast cancer[7]. Fulvestrant is also a hormone therapy that works by blocking and degrading estrogen receptors.
  • Palbociclib + Cetuximab: This combination is being studied for the treatment of head and neck cancer[4]. Cetuximab is a targeted therapy that blocks a protein called EGFR, which is often overactive in head and neck cancers.

Potential Side Effects

Like all medications, palbociclib can cause side effects. Some of the most common side effects reported in clinical trials include:

  • Neutropenia: A decrease in white blood cells, which can increase the risk of infections[6].
  • Fatigue: Feeling tired or weak[6].
  • Nausea and Vomiting[6].
  • Decreased Appetite[6].
  • Hair Loss[6].
  • Diarrhea[6].

It’s important to note that not everyone experiences these side effects, and your healthcare team will monitor you closely during treatment to manage any side effects that may occur.

Ongoing Clinical Trials

Researchers are continuously studying palbociclib to understand its full potential and improve its use in cancer treatment. Some ongoing areas of research include:

  • Combination with Other Therapies: Studies are exploring the effectiveness of palbociclib when combined with various other cancer treatments[1].
  • Use in Different Cancer Types: While primarily used for breast cancer, researchers are investigating palbociclib’s potential in treating other cancers, such as head and neck cancer and pancreatic cancer[4][5].
  • Biomarker Studies: Researchers are looking at specific biomarkers (such as p16 and Rb expression) to identify which patients might benefit most from palbociclib treatment[4].

Impact on Patient Quality of Life

In addition to studying the effectiveness of palbociclib in treating cancer, researchers are also interested in understanding how the medication affects patients’ overall quality of life. Some studies have used questionnaires like the EORTC QLQ-C30 and EORTC QLQ-H&N35 to assess various aspects of patient well-being during treatment[4]. These assessments help healthcare providers better understand the full impact of palbociclib treatment on patients’ daily lives and can inform decisions about treatment plans.

Aspect Details
Drug Name Palbociclib (PD-0332991)
Mechanism of Action Selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6)
Cancer Types Studied Breast cancer, non-small cell lung cancer, acute leukemia, gastrointestinal stromal tumors, brain tumors
Administration Oral, typically 125 mg daily for 21 days, followed by 7 days off
Key Outcomes Measured Progression-free survival, overall survival, tumor response, safety/tolerability
Common Side Effects Low blood cell counts, fatigue, nausea, diarrhea
Biomarkers of Interest Retinoblastoma (RB) protein status, CCND1/2/3 amplification
Combination Therapies Studied with hormone therapies, chemotherapies, and targeted agents

FAQ

  • What types of cancer is palbociclib being studied for? Palbociclib is being investigated for several cancer types, including breast cancer, non-small cell lung cancer, acute leukemia, gastrointestinal stromal tumors, and brain tumors like oligodendroglioma and oligoastrocytoma.
  • How is palbociclib typically administered in clinical trials? In most trials, palbociclib is given orally as a daily dose for 21 days, followed by a 7-day break. This 28-day cycle is repeated as long as the patient is benefiting and tolerating the treatment.
  • What are some common side effects of palbociclib? Common side effects may include low blood cell counts, fatigue, nausea, and diarrhea. However, the full range of side effects is still being studied in clinical trials.
  • How do researchers determine if palbociclib is working? Researchers assess the effectiveness of palbociclib by measuring tumor response (shrinkage), progression-free survival (time without cancer growth), and overall survival. They also monitor for side effects and quality of life impacts.
  • Who might be eligible to participate in a palbociclib clinical trial? Eligibility varies by trial, but often includes patients with specific cancer types that have progressed after standard treatments. Some trials look for certain genetic markers in tumors. Patients must meet health criteria and be willing to comply with study procedures.

Ongoing Clinical Trials on Palbociclib

  • Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Italy The Netherlands +3

  • Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Bulgaria Czechia France Germany Hungary +4

  • Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Portugal

  • Study on the Safety of AZD8421 Alone or with Drug Combination for Patients with Advanced Breast Cancer and High-Grade Ovarian Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Study on Personalized Treatment for Metastatic Colorectal Cancer Using Methotrexate and Drug Combination for Patients with Advanced Disease

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study of Palbociclib and Fulvestrant for Women with Advanced Breast Cancer After Previous CDK4/6 Inhibitor and Hormonal Therapy

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study on the Effectiveness and Safety of Tocilizumab and Drug Combination for Patients with Metastatic Breast Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Spain

  • Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Optimizing CDK 4/6 Inhibitors and Endocrine Therapy for Older Patients with Advanced Breast Cancer Using Abemaciclib, Palbociclib, and Ribociclib

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland Greece Italy Norway Spain Sweden

Glossary

  • Cyclin-dependent kinases (CDK): Proteins that play a crucial role in regulating cell division and growth. Palbociclib specifically targets CDK4 and CDK6.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Dose-limiting toxicity (DLT): Side effects severe enough to prevent an increase in the dose of a drug being tested in a clinical trial.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Retinoblastoma protein (RB): A tumor suppressor protein that helps control cell growth and division. Its presence is often important for palbociclib to be effective.
  • Anaplastic: A term used to describe cancer cells that divide rapidly and have little or no resemblance to normal cells.
  • Oligodendroglioma: A type of brain tumor that begins in cells called oligodendrocytes, which support and protect nerve cells.

References

  1. https://clinicaltrials.gov/study/NCT04129151
  2. https://clinicaltrials.gov/study/NCT02499146
  3. https://clinicaltrials.gov/study/NCT02600923
  4. https://clinicaltrials.gov/study/NCT02499120
  5. https://clinicaltrials.gov/study/NCT02501902
  6. https://clinicaltrials.gov/study/NCT02679755
  7. https://clinicaltrials.gov/study/NCT05226871